





2/20/2025

Health Insurance Marketplace (HIM) Formulary Updates

January 2025

The changes below are reflective of Capital Rx P&T Committee decisions.

2025 FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Status	Effective Date
Antiviral	Areptude 600MG ER	Tier 2 – Preferred Brand, ACA	2/1/2025
Gastrointestinal Agent	lqirvo 80MG	Tier 4 - Specialty PA, QL	2/1/2025
Neuromuscular Agent	Duvyzat 8.86MG	Tier 4 - Specialty PA, QL	2/1/2025
Respiratory Tract/Pulmonary Agent	Airsupra 90/80MCG	Tier 2 – Preferred Brand	2/1/2025

YEAR-TO-DATE FORMULARY GENERIC RELEASES

(generic drug is available at copay listed once drug is available on the market)

Therapeutic Class	Medication	Formulary Status	Effective date

YEAR-TO-DATE FORMULARY CHANGES

Therapeutic Class	Medication	Formulary Status	Effective date
Long-Acting Insulin	Lantus SoloStar/ Lantus	Excluded	1/1/2025
Histamine H2- Antagonist	Famotidine	Excluded	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Attention Deficit Disorder Agents	Lisdexamfetamine Dimesylate	Tier 1 - Generic	1/1/2025
Nonsteroidal Anti- Inflammatory Agent	Diclofenac Sodium	Excluded	1/1/2025
Attention Deficit Disorder Agents	Vyvanse	Excluded	1/1/2025
Proton-Pump Inhibitor	Esomeprazole Magnesium	Excluded	1/1/2025
Gastrointestinal Agents	Linzess capsules	Excluded	1/1/2025
Nonsteroidal Anti- Inflammatory Agent	Diclofenac Sodium	Excluded	1/1/2025
Respiratory Tract / Pulmonary Agents	Fluticasone Propinate HFA	Excluded	1/1/2025
Antibacterials	Clindamycin Phos-Benzoyl Perox	Excluded	1/1/2025
Proton-Pump Inhibitor	Esomeprazole Magnesium	Excluded	1/1/2025
Gastrointestinal Agents	Linzess capsules	Excluded	1/1/2025
Respiratory Tract / Pulmonary Agents	Fluticasone Propinate HFA	Excluded	1/1/2025
Antibacterials	Clindamycin Phos-Benzoyl Perox	Excluded	1/1/2025
Therapeutic Agent	Omega-3-acid Ethyl Esters	Excluded	1/1/2025
Anti-Inflammatory Agent	Cyclosporine	Excluded	1/1/2025
Antimuscarinic/ Antispasmodic	Hyoscyamine Sulfate	Excluded	1/1/2025
Interleukin-Mediated Agent	Taltz	Excluded	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Dipeptidyl Peptidase-4 Inhibitor	Tradjenta tablets	Excluded	1/1/2025
Keratolytic Agent	Adapalene-Benzoyl Peroxide	Excluded	1/1/2025
Incretin Mimetics	Victoza	Excluded	1/1/2025
Botulinum Toxin	Botox	Excluded	1/1/2025
Atypical Antipsychotics	Invega Sustenna	Excluded	1/1/2025
Prostaglandin Analog	Lumigan solution	Excluded	1/1/2025
Adrenal	Pulmicort Flexhaler	Excluded	1/1/2025
Devices/Supplies	Alcohol Prep	Excluded	1/1/2025
Blood Glucose Monitoring	Contour Next EZ	Excluded	1/1/2025
Bone-Modifying Agent	Prolia	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	Compact Space Chamber	Excluded	1/1/2025
Antivirals	Epclusa	Excluded	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Antimuscarinic/ Antispasmodic	Tiotropium Bromide Monohydrate capsules	Excluded	1/1/2025
Devices/Supplies	BD Swab Single Use Regular	Excluded	1/1/2025
Incretin Mimetics	Liraglutide	Excluded	1/1/2025
Antimuscarinic/ Antispasmodic	Tiotropium Bromide Monohydrate capsules	Excluded	1/1/2025
Devices/Supplies	BD Swab Single Use Regular	Excluded	1/1/2025
Incretin Mimetics	Liraglutide	Excluded	1/1/2025
Bile Acid Sequestrants	Cholestyramine powder	Excluded	1/1/2025
Atypical Antipsychotics	Abilify Maintena	Excluded	1/1/2025
Atypical Antipsychotic	Quetiapine Fumarate tablet	Excluded	1/1/2025
Anthelmintic	Ivermectin	Excluded	1/1/2025
Devices/Supplies	Alcohol Swabs	Excluded	1/1/2025
Ophthalmic Agents	Brimonidine Tartrate	Excluded	1/1/2025
Dermatological Agents	Tretinoin	Excluded PA added	1/1/2025
Somatotropin Agonist	Norditropin FlexPro	Excluded	1/1/2025
Butyrophenone	Haloperidol Decanoate	Excluded	1/1/2025
Immunomodulatory Agent	Pimecrolimus cream	Excluded	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Histamine H2-Antagonist	Cimetidine	Excluded	1/1/2025
Nonsteroidal Anti-Inflammatory Agent	Diclofenac Sodium ER tablets	Excluded	1/1/2025
Opioid Partial Agonists	Buprenorphine TD Patch Weekly	Excluded	1/1/2025
Devices/Supplies	OptiChamber Diamond-Lg Mask	Excluded	1/1/2025
Amphetamine	Amphetamine Sulfate tablets	Excluded	1/1/2025
Devices/Supplies	CeQur Simplicity 2U	Excluded	1/1/2025
GI Drug/Misc.	Motegrity tablets	Excluded	1/1/2025
Devices/Supplies	OptiChamber Diamond	Excluded	1/1/2025
Keratolytic Agent	Adapalene 0.3% Gel	Excluded PA Added	1/1/2025
Selective Beta-2- Adrenergic Agonist	Formoterol Fumerate	Excluded	1/1/2025
Multivitamin Preparation	Prenatal 27-1mg tablets	Excluded	1/1/2025
Devices/Supplies	EQ Space Chamber Anti-Static M	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor Misc.	Simponi	Excluded	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Opioid Agonist	OxyContin tablet	Excluded	1/1/2025
Opioid Antagonist	Vivitrol	Excluded	1/1/2025
rrigating Solution	Sodium Chloride 0.9% NEBU	Excluded	1/1/2025
Devices/Supplies	ProChamber VHC	Excluded	1/1/2025
Bile Acid Sequestrants	Cholestyramine Light 4GM pack	Excluded	1/1/2025
Devices/Supplies	CVS Alcohol Prep pads	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	Compact Space Chamber large mask	Excluded	1/1/2025
Antimigraine Agents	Zolmitriptan ODT	Excluded	1/1/2025
Cyclic Lipopeptide Antibiotic	Daptomycin SOLR	Excluded	1/1/2025
Opioid Agonist	Oxycodone HCl 5MG capsules	Excluded	1/1/2025
Vasoconstrictors	Epinephrine	Excluded	1/1/2025
Dipetidyl Peptidase-4 (DPP-4) Inhibitor	Jentadueto/Jentadueto XR tablets	Excluded	1/1/2025
Reversible Cox-1/Cox-2 Inhibitor	Ketorolac Tromethamine solution	Excluded	1/1/2025
Devices/Supplies	EQ Space Chamber Anti-static	Excluded	1/1/2025
Fibric Acid Derivative	Fenofibric Acid CPDR	Excluded	1/1/2025
Devices/Supplies	Easy Touch Alcohol Prep Medium	Excluded	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Carbapenem Antibiotic	Ertapenem Sodium	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc.	Inflectra solution	Excluded	1/1/2025
Adrenal	Flovent HFA	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	AeroChamber Pls FloVu Mouthpiece	Excluded	1/1/2025
Devices/Supplies	Compact Space Chamber/Med Mask	Excluded	1/1/2025
Opioid Agonist	Hydrocodone-Acetaminophen	Excluded	1/1/2025
Nonergot-Deriv Dopamine Receptor Agonist	Ropinirole HCI ER 24 tablet	Excluded	1/1/2025
Devices/Supplies	AeroChamber Plus Flo-Vu large	Excluded	1/1/2025
Devices/Supplies	OptiChamber Diamond-Md Mask	Excluded	1/1/2025
Anticonvulsant Misc	Lamotrigine TBDP	Excluded	1/1/2025
Basic Ointment and Protectant	Calcipotriene Ointment	Excluded	1/1/2025
Basic Ointment and Protectant	Xiaflex	Excluded	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Vitamin B Complex	Cyanocobalamin 500 MCG/0.1ML solution	Excluded	1/1/2025
Parathyroid Agent	Teriparatide 620 MCG/2.48ML SOPN	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc.	Simponi Aria solution	Excluded	1/1/2025
Devices/Supplies	Contour Next Monitor	Excluded	1/1/2025
Adrenal	Triamcinolone Acetonide suspension	Excluded	1/1/2025
Devices/Supplies	OptiChamber/ OptiChamber Diamond- Sm mask	Excluded	1/1/2025
Bile Acid Sequestrant	Prevalite 4gm pack	Excluded	1/1/2025
Benzodiazepine	Lorazepam 2MG/ML solution	Excluded	1/1/2025
Selective-Serotonin Reuptake Inhibitor	Fluvoxamine Maleate ER cap24	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	Vortex Valved Holding Champer	Excluded	1/1/2025
Devices/Supplies	Alcohol Pads	Excluded	1/1/2025
Multivitamin	Folbee Plus	Excluded	1/1/2025
Antimuscarinics	Fesoterodine Fumarate ER	Excluded	1/1/2025
Devices/Supplies	Pharmacist Choice Alcohol pads	Excluded	1/1/2025
Blood Derivatives	Prolastin-C solution	Excluded	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Immunomodulatory Agent	Tysabri 300MG/15ML conc	Excluded	1/1/2025
Hematopoietic Agent	Neulasta SOSY	Excluded	1/1/2025
Iron Preparation	Se-Tan PLUS capsules	Excluded	1/1/2025
Contraceptive	Opill	Excluded	1/1/2025
Respiratory Smoothe Muscle Relaxant	Theophylline ER TB12	Excluded	1/1/2025
Ophthalmic Agent	Alphagan P solution	Excluded	1/1/2025
Devices/Supplies	UltiCare Alcohol swabs	Excluded	1/1/2025
Devices/ Supplies	HM Sterile Alcohol Prep	Excluded	1/1/2025
Interleukin Antagonist	Ilaris	Excluded	1/1/2025
Opioid Partial Agonist	Pentazocine-Naloxone HCl	Excluded	1/1/2025
Androgen	Testosterone 40.5MG/2.5GM (1.62%) gel	Excluded	1/1/2025
Gonadotropin	Pregnyl	Excluded	1/1/2025
Iron Preparation	Trigels-F Forte capsules	Excluded	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Central Nervous System Agent, Misc.	Memantine HCI ER	Excluded	1/1/2025
Prostacyclin & Prostacyclin Derivative	Tyvaso DPI Titration Kit	Excluded	1/1/2025
HIV Protease Inhibitor Antiretroviral	Prezista	Excluded	1/1/2025
Incretin Mimetic	Byetta 5 and 10 MCG Pen	Excluded	1/1/2025
Atypical Antipsychotic	Risperidone Microspheres ER	Excluded	1/1/2025
Interleukin-Mediated Agent, Misc.	Kineret injection	Excluded	1/1/2025
Somatotropin Agonist	Nutropin AQ NuSpin 10	Excluded	1/1/2025
Adrenal	Flovent Diskus	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor Misc.	Avsola injection	Excluded	1/1/2025
Cholelitholytic Agent	Cholbam capsules	Excluded	1/1/2025
Vitamin B Complex	FaBB tablets	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	Microspacer	Excluded	1/1/2025
Parasympathomimetic (Cholinergic Agent)	Pyridostigmine Bromide 30mg tablets	Excluded	1/1/2025
Fumarates	Bafiertam capsules	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc	Cimzia 2x 200 MG kit	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	EQ Space Chamber Anti-Static S	Excluded	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Atypical Antipsychotic	Risperdal Consta	Excluded	1/1/2025
Complement Inhibitor	Ultomiris solution	Excluded	1/1/2025
Devices/Supplies	Contour Next One	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc.	Hyrimoz-Plaq Psor/Uveit start	Excluded	1/1/2025
Devices/Supplies	OneTouch UltraSoft Lancets	Excluded	1/1/2025
Direct Thrombin Inhibitor	Pradaxa 110MG capsules	Excluded	1/1/2025
Antineoplastic Agent	Ruxience solution	Excluded	1/1/2025
Non-Opioid Analgesic	Butalbital-APAP-Caff-Cod 50-300-40- 30MG capsules	Excluded	1/1/2025
Heavy Metal Antagonists	Deferasirox TBSO	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc.	Cyltezo (2 Pen)	Excluded	1/1/2025
Phosphodiesterase Type 5 Inhibitor	Sildenafil Citrate suspension	Excluded	1/1/2025
Multivitamin Preparation	Triphrocaps	Excluded	1/1/2025
Fibric Acid	Fenofibrate Micronized 43 MG capsules	Excluded	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Prostacylin & Prostacylin Derivative	Tyvaso DPI Maintenance kit	Excluded	1/1/2025
Antitoxins and Immune Globulin	Hizentra	Excluded	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc.	Hyrimoz injection	Excluded	1/1/2025
Devices/Supplies	SM Alcohol Prep	Excluded	1/1/2025
Anti-Inflammatory Agent (Respiratory)	Nucala 100 MG Solution	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	AeroChamber Plus Flo-Vu w/mask	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	Vortex Hold Chamber/mask/child	Excluded	1/1/2025
Iron Preparation	Na Ferric Gluc Cplx in Sucrose	Excluded	1/1/2025
Antineoplastic Agent	Votrient tablets	Excluded	1/1/2025
Interleukin Inhibitor Agent, Misc.	Xolair 150 MG Solution	Excluded	1/1/2025
Devices/Supplies	AeroChamber Plus Flo-Vu w/mask	Excluded	1/1/2025
Devices/Supplies	Vortex Hold Chmbr/mask/child	Excluded	1/1/2025
Spacer/ Aerosol-Holding Chamber	AeroChamber Z-Stat Plus Chamber	Excluded	1/1/2025
Devices/Supplies	Aero Chamber Plus Flo-Vu Medium	Excluded	1/1/2025
Bone Resorption Inhibitor	Zoledronic Acid	Excluded	1/1/2025
Multivitamin	PNV-DHA capsules	Excluded	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Antivirals	Harvoni tablets	Excluded	1/1/2025
Multivitamin Preparation	PNV-Omega	Excluded	1/1/2025
Contraceptive	Etonogestrel-Ethinyl Estradiol	Excluded	1/1/2025
Contraceptive	Nexplanon Implant	Excluded	1/1/2025
Contraceptive	EnilloRing	Excluded	1/1/2025
Contraceptive	EluRyng	Excluded	1/1/2025
Contraceptive	Haloette	Excluded	1/1/2025
Multivitamin	Prenatal	Excluded	1/1/2025
Multivitamin	Prenatal Vitamins	Excluded	1/1/2025
Contraceptive	Gemmily tablets	Excluded	1/1/2025
Contraceptive	Annovera VA Ring	Excluded	1/1/2025
Contraceptive	Levonorgest-Eth Estradiol-Iron	Excluded	1/1/2025
Contraceptive	Joyeaux tablets	Excluded	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Smoking Cessation Agent	Nicorette gum	Excluded	1/1/2025
Multivitamin	Prenatal (w/Iron & folic acid)	Excluded	1/1/2025
Contraceptive	Norethin Ace-eth estrad-FE tablets	Excluded	1/1/2025
Smoking Cessation Agent	NicoDerm CQ patch	Excluded	1/1/2025
Smoking Cessation Agent	NicoDerm CQ patch	Excluded	1/1/2025
Multivitamin	Prenatal/Iron	Excluded	1/1/2025
Multivitamin	Classic Prenatal	Excluded	1/1/2025
Multivitamin	One-A-Day Women's Prenatal 1	Excluded	1/1/2025
Contraceptive	Mirena (52 MG)	Excluded	1/1/2025
Contraceptive	Paragard Intrauterine Copper	Excluded	1/1/2025
Contraceptive	Kyleena	Excluded	1/1/2025
Contraceptive	Skyla	Excluded	1/1/2025
Contraceptive	Liletta	Excluded	1/1/2025
Rapid-Acting Insulin	Insulin Lispro	PA Added	1/1/2025
Rapid-Acting Insulin	Humalog KwikPen/ Humalog Humalog Junior KwikPen	PA Added	1/1/2025
Intermediate-Acting Insulin	Humulin 70/30/ Humulin 70/30 KwikPen	PA Added	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Rapid-Acting Insulin	Humalog Mix 75/25 KwikPen Humalog Mix 75/25	PA Added	1/1/2025
Intermediate-Acting Insulin	Humulin N / Humulin N KwikPen	PA Added	1/1/2025
Short-Action Insulin	Humulin R	PA Added	1/1/2025
Calcitonin Gene-Related Peptide Antag.	Qulipta tablets	PA Added	1/1/2025
Chloride Channel Activators	Lubiprostone capsules	PA Added	1/1/2025
Antineoplastic Agent	Fluorouracil	PA Added	1/1/2025
Calcitonin Gene-Related Peptide Antag	Emgality	PA Added	1/1/2025
Omega-3-Mediated Antilipemics	Vascepa capsules	PA Added	1/1/2025
Antineoplastic Agent	Capecitabine tablets	PA Added	1/1/2025
Vesicular Monoamine Transport 2 Inhibitor	Ingrezza capsules	PA Added	1/1/2025
Anti-Inflammatory Agents	Xiidra solution	PA Added	1/1/2025
Anti-Inflammatory Agents	Xiidra solution	PA Added	1/1/2025
Anti-Inflammatory Agents	Miebo solution	PA Added	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
ACL Inhibitors	Nexlizet tablets	PA Added	1/1/2025
Janus Kinase Inhibitor	Sotyktu tablets	PA Added	1/1/2025
Rapid-Acting Insulin	Insulin Aspart FlexPen / Insulin Aspart	PA Added	1/1/2025
Omega-3-Mediated Antilipemics	Icosapent Ethyl capsules	PA Added	1/1/2025
Devices/Supplies	Omnipod DASH Pods (Gen 4)	PA Added	1/1/2025
Guanylate Cyclase C (GCC) Recept Agonist	Trulance tablets	PA Added	1/1/2025
Janus Kinase Inhibitor	Olumiant tablets	PA Added	1/1/2025
Anti-Inflammatory Agents	Xiidra solution	PA Added	1/1/2025
Anti-Inflammatory Agents	Miebo solution	PA Added	1/1/2025
ACL Inhibitors	Nexlizet tablets	PA Added	1/1/2025
Janus Kinase Inhibitor	Sotyktu tablets	PA Added	1/1/2025
Rapid-Acting Insulin	Insulin Aspart FlexPen/Insulin Aspart	PA Added	1/1/2025
Omega-3-Mediated Antilipemics	Icosapent Ethyl capsules	PA Added	1/1/2025
Devices/Supplies	Omnipod DASH Pods (Gen 4)	PA Added	1/1/2025
Guanylate Cyclase C (GCC) Recept Agonist	Trulance tablets	PA Added	1/1/2025
Janus Kinase Inhibitor	Olumiant tablets	PA Added	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Central Nervous System Agents, Misc.	Xywav solution	PA Added	1/1/2025
Interleukin Antagonist	Fasenra Pen/ Fasenra	PA Added	1/1/2025
Antigonadropin	Orilissa tablets	PA Added	1/1/2025
Immunomodulatory Agent	Adbry solution	PA Added	1/1/2025
Interleukin Antagonist	Tezspire solution	PA Added	1/1/2025
Antineoplastic Agent	Brukinsa capsules	PA Added	1/1/2025
EENT Drug, Misc.	Tyrvaya solution	PA Added	1/1/2025
Anti-Inflammatory Agent	Cequa solution	PA Added	1/1/2025
Cystic Fibrosis (CFTR) Correctors	Trikafta tablets	PA Added	1/1/2025
Parathyroid Agent	Tymlos solution	PA Added	1/1/2025
Disease-Modifying Antirheumatic Drug Misc.	Entyvio solution	PA Added	1/1/2025
Antineoplastic Agent	Kisqali (600 MH Dose) tablets	PA Added	1/1/2025
Vesicular Monoamine Transport 2 Inhibitor	Austedo/Austedo XR tablets	PA Added	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Anticonvulsants, Misc.	Trokendi XR capsules	PA Added	1/1/2025
Antigonadtropins	Myfembree tablets	PA Added	1/1/2025
Antineoplastic Agent	Erleada tablets	PA Added	1/1/2025
Cholelitholytic Agents	Ocaliva tablets	PA Added	1/1/2025
Fumarates	Vumerity capsules	PA Added	1/1/2025
T-Cell Blocker	Lupkynis capsules	PA Added	1/1/2025
Dermatological Agents	Qbrexza	PA Added	1/1/2025
Antigonadtropin	Oriahnn capsules	PA Added	1/1/2025
Immunomodulatory Agent	Zeposia capsules	PA Added	1/1/2025
Vasopressin Antagonist	Jynarque tablet	PA Added	1/1/2025
Interleukin-Mediated Agents, Misc.	Kevzara solution	PA Added	1/1/2025
Anti-Inflammatory Agent (EENT)	Vevye solution	PA Added	1/1/2025
Rapid-Acting Insulin	Humalog Mix 50/50 KwikPen	PA Added	1/1/2025
Janus Kinase Inhibitor	Litfulo capsules	PA Added	1/1/2025
Antineoplastic Agent	Nubeqa tablets	PA Added	1/1/2025
Vasodilating Agent, Misc.	Uptravi/Uptravi Titration	PA Added	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
ACL Inhibitor	Nexletol tablets	PA Added	1/1/2025
PCSK9 Inhibitor	Praluent solution	PA Added	1/1/2025
CGMP Synthesis Agent	Verquvo tablet	PA Added	1/1/2025
Hematopoietic Agent	Doptelet tablet	PA Added	1/1/2025
Pituitary	Skytrofa injection	PA Added	1/1/2025
Kallikrein	Orladeyo capsules	PA Added	1/1/2025
Androgen	Jatenzo capsules	PA Added	1/1/2025
Blood Form, Coag, Thrombosis Agent Misc.	Tavalisse tablets	PA Added	1/1/2025
GI Drug, Misc.	Ibsrela tablets	PA Added	1/1/2025
Rapid-Acting Insulin	Lyumjev KwikPen /Lyumjev solution	PA Added	1/1/2025
Antineoplastic Agent	Truqap tablets	PA Added	1/1/2025
Antineoplastic Agent	Xospata tablets	PA Added	1/1/2025
Corticosteroids	Xhance	PA Added	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Antineoplastic Agent	Fruzaqla capsule	PA Added	1/1/2025
Antineoplastic Agent	Tibsovo tablets	PA Added	1/1/2025
Keratolytic Agent	Aklief cream	PA Added	1/1/2025
Antineoplastic Agent	Calquence	PA Added	1/1/2025
Atypical Antipsychotic	Nuplazid	PA Added	1/1/2025
Antineoplastic Agent	Kisqali (400 MG Dose) tablets	PA Added	1/1/2025
Calcitonin Gene-Related Peptide Antag	Zavzpret spray	PA Added	1/1/2025
Interleukin Antagonists	Arcalyst injection	PA Added	1/1/2025
Ammonia Detoxicant	Pheburane oral pellets	PA Added	1/1/2025
Immunomodulatory Agent	Velsipity tablets	PA Added	1/1/2025
Endothelin Receptor Antagonist	Filspari tablets	PA Added	1/1/2025
Adrenals	Isturisa tablets	PA Added	1/1/2025
Kallikrein	Takhzyro injection	PA Added	1/1/2025
Antineoplastic Agent	Balversa tablets	PA Added	1/1/2025
Androgen	Danazol	PA Added	1/1/2025
Antineoplastic Agent	Besremi solution	PA Added	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Rapid-Acting Insulins	Afrezza powder	PA Added	1/1/2025
Pituitary	Ngenla pen	PA Added	1/1/2025
Hemostatic	Jivi injection	PA Added	1/1/2025
Misc. Therapeutic Agent	Voxzogo injection	PA Added	1/1/2025
Antineoplastic Agent	Ojjaara tablets	PA Added	1/1/2025
Antineoplastic Agent	Welireg tablets	PA Added	1/1/2025
Alpha- And Beta- Adrenergic Agonist	Droxidopa capsules	PA Added	1/1/2025
Alpha- And Beta- Adrenergic Agonist	Droxidopa capsules	PA Added	1/1/2025
Antineoplastic Agent	Pemazyre tablets	PA Added	1/1/2025
Antineoplastic Agent	Mektovi tablets	PA Added	1/1/2025
Immunomodulatory Agent	Plegridy injection	PA Added	1/1/2025
Cyclooxygenase-2 (COX-2) Inhibitor	Elyxyb solution	PA Added	1/1/2025
Wakefulness-Promoting Agents	Xyrem solution	PA Added	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Melatonin Receptor Agonist	Hetlioz LQ suspension	PA Added	1/1/2025
Keratolytic Agent	Arazlo lotion	PA Added	1/1/2025
Gastrointestinal Agents	Movantik tablets	PA Added	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc.	Zymfentra (2 Pen)	PA Added	1/1/2025
Enzymes	Palynziq syringe	PA Added	1/1/2025
Antineoplastic Agent	Nerlynx tablets	PA Added	1/1/2025
Thyroid Agent	NP Thyroid tablets	Tier 2 – Preferred Brand	1/1/2025
Estrogen	Premarin tablets, cream	Tier 3 – Non-preferred Brand	1/1/2025
Thyroid Agent	Thyroid tablets	Tier 2 – Preferred Brand	1/1/2025
HCV Protease Inhibitor Antiviral	Mavyret tablets, pellets	Tier 4 - Specialty	1/1/2025
Glycogenolytic Agent	Glucagon Emergency	Tier 3 – Non- Preferred Brand	1/1/2025
Incretin Mimetic	Bydureon Bcise auto-injector	Tier 3 – Non- Preferred Brand	1/1/2025
Antiparathyroid Agent	Cinacalcet HCI tablets	Tier 4 - Specialty	1/1/2025
Androgen	Testosterone Enanthate injection	Tier 2 – Preferred Brand	1/1/2025
Sulfonylurea	Glyburide Micronized	Tier 2 – Preferred Brand	1/1/2025
Fumarate	Dimethyl Fumerate capsules	Tier 4 - Specialty	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Amyotrophic Lateral Sclerosis (ALS) Agent	Riluzole tablets	Tier 4 - Specialty	1/1/2025
Beta-Adrenergic Blocking Agent (EENT)	Levobunolol HCl solution	Tier 2 - Preferred Brand	1/1/2025
Antineoplastic Agent	Methotrexate Sodium tablets, injection	Tier 2 - Preferred Brand	1/1/2025
Heavy Metal Antagonist	Deferiprone tablets	Tier 4 - Specialty	1/1/2025
Opioid Agonist	Hydrocodone-Ibuprofen tablets	Tier 2 - Preferred Brand	1/1/2025
Opioid Agonist	Morphine Sulfate capsules	Tier 1 - Preferred Generic	1/1/2025
Histamine H2- Antagonist	Nizatidine capsules	Tier 2 - Preferred Brand	1/1/2025
Beta-Adrenergic Blocking Agent	Propranolol HCl tablets	Tier 2 - Preferred Brand	1/1/2025
Anti-HIV Agents	Rukobia tablets	Tier 3 - Non-Preferred Brand	1/1/2025
5-HT3 Receptor Antagonist	Ondansetron/Ondansetron HCl	QL added	1/1/2025
Incretin Mimetics	Mounjaro solution	QL added	1/1/2025
Selective Serotonin Agonist	Rizatriptan Benzoate tablets	QL added	1/1/2025
Opioid Partial Agonist	Buprenorphine HCI	QL added	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.

Therapeutic Class	Medication	Formulary Status	Effective date
Anticoagulants	Enoxaparin Sodium	QL added	1/1/2025
Diabetic Devices/Supplies	Dexcom G6 Transmitter	QL added	1/1/2025
Reversible Cox-1/Cox-2 Inhibitor	Ketorolac Tromethamine	QL added	1/1/2025
Estrogen	Estradiol tablets	QL added	1/1/2025
Selective Serotonin	Eletriptan Hydrobromide tablets	QL added	1/1/2025
Incretin Mimetics	Rybelsus tablets	QL added	1/1/2025
Antimigraine Agents	Sumatriptan Succinate tablets	QL added	1/1/2025
Antiprolifrant	Imiquimod cream	QL added	1/1/2025
Antivirals	Lagevrio capsules	QL added	1/1/2025
Antiprotozoals, Cryptosporidiosis	Nitazoxanide tablets	QL added	1/1/2025
Diabetic Devices/Supplies	Dexcom G7 Receiver	QL added	1/1/2025
Selective Serotonin Agonist	Almotriptan Malate tablets	QL added	1/1/2025
5-HT3 Receptor Agonist	Sancuso patch	QL added	1/1/2025
Antimigraine Agents	Zolmitriptan tablets	QL added	1/1/2025
Gonadotropin	Pregnyl injection	QL added	1/1/2025
Immunomodulatory Agent	Skyrizi Pen, injection	QL added	1/1/2025

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.







Therapeutic Class	Medication	Formulary Status	Effective date
Immunomodulatory Agent	Bimzelx solution	QL added	1/1/2025
Diabetic Devices/Supplies	Omnipod 5 G6 Intro (Gen 5)	QL added	1/1/2025
Tumor Necrosis Factor Inhibitor, Misc.	Enbrel Injection	QL added	1/1/2025
Antimigraine Agents	Ubrelvy tablets	PA, QL added	1/1/2025
Calcitonin Gene-Related Peptide Antagonist	Nurtec ODT tablets	QL added	1/1/2025
Antimigraine Agents	Reyvow tablet	PA, QL, AL added	1/1/2025

<u>Key</u>

PA= Prior Authorization AL= Age Limit ST= Step Therapy QL=Quantity Limit NF=Non-formulary ACA = \$0 Preventive Coverage

Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brand/generic; Tier 4= Specialty

When generics become available on the EHB formulary, the brand moves to Excluded status. Drugs may be subject to coverage requirements or limits such as prior authorization. Refer to your formulary or plan documents for additional information.